Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
A 'mix and match' approach to SARS-CoV-2 vaccination | Nature Medicine
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Vaccines | Free Full-Text | Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination | NEJM
Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens - ScienceDirect
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data - The Lancet
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
Covid-19 vaccine mixing: could heterologous boosters improve immunity?
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Nature Medicine
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine - ScienceDirect
Heterologous Covid-19 Booster Vaccinations | NEJM
What is a heterologous booster vaccine? | The Hindu - YouTube
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 - The Lancet Infectious Diseases
Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans | NEJM
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
